Limits...
Ki-67 Antigen Overexpression Is Associated with the Metaplasia-Adenocarcinoma Sequence in Barrett's Esophagus.

Volkweis BS, Gurski RR, Meurer L, Pretto GG, Mazzini Gda S, Edelweiss MI - Gastroenterol Res Pract (2012)

Bottom Line: Ki-67 expression was significantly different between all groups (P < 0.05).In patients with cancer, Ki-67 was not associated with clinical or surgical staging.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Hospital de Clínicas de Porto Alegre, School of Medicine, Federal University of Rio Grande do Sul, 90035-903 Porto Alegre, RS, Brazil.

ABSTRACT
Introduction. The objective of this study was to evaluate Ki-67 antigen expression in patients with Barrett's esophagus and esophageal adenocarcinoma and to assess its correlation with the metaplasia-esophageal adenocarcinoma progression. Methods. Using immunohistochemistry we evaluated the Ki-67 index in patients with Barrett's esophagus, esophageal adenocarcinoma, and controls. We included patients with endoscopically visible columnar mucosa of the distal esophagus (whose biopsies revealed specialized intestinal-type metaplasia), patients with esophageal and esophagogastric tumors types I and II, and patients with histologically normal gastric mucosa (control). Results. In the 57 patients studied there were no statistically significant differences between the groups with respect to age or race. Patients with cancer were predominantly men. The Ki-67 index averaged 10 ± 4 % in patients with normal gastric mucosa (n = 17), 21 ± 15 % in patients with Barrett's esophagus (n = 21), and 38 ± 16 % in patients with cancer (n = 19). Ki-67 expression was significantly different between all groups (P < 0.05). There was a strong linear correlation between Ki-67 expression and the metaplasia-adenocarcinoma sequence (P < 0.01). In patients with cancer, Ki-67 was not associated with clinical or surgical staging. Conclusions. Ki-67 antigen has increased expression along the metaplasia-adenocarcinoma sequence. There is a strong linear correlation between Ki-67 proliferative activity and Barrett's carcinogenesis.

No MeSH data available.


Related in: MedlinePlus

Example of immunohistochemical staining for Ki-67 antigen in esophageal adenocarcinoma under 200x microscopic magnification (stained cells are marked with an arrow).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3401558&req=5

fig4: Example of immunohistochemical staining for Ki-67 antigen in esophageal adenocarcinoma under 200x microscopic magnification (stained cells are marked with an arrow).

Mentions: The average overall Ki-67 index was 23.62 ± 17.6%. The average Ki-67 was 10.29 ± 4.6% in the controls, 21.26 ± 15.1% in the BE patients, and 38 ± 16% in the EAC patients (Figures 3 and 4). Ki-67 increased through groups 1 to 3, and there was a significant difference in the Ki-67 index among all three groups (Figure 5). There was a strong linear correlation (r = 0.6) between Ki-67 and the progression from control to metaplasia to adenocarcinoma (Figure 6) (P < 0.01). No significant interobserver variability was found.


Ki-67 Antigen Overexpression Is Associated with the Metaplasia-Adenocarcinoma Sequence in Barrett's Esophagus.

Volkweis BS, Gurski RR, Meurer L, Pretto GG, Mazzini Gda S, Edelweiss MI - Gastroenterol Res Pract (2012)

Example of immunohistochemical staining for Ki-67 antigen in esophageal adenocarcinoma under 200x microscopic magnification (stained cells are marked with an arrow).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3401558&req=5

fig4: Example of immunohistochemical staining for Ki-67 antigen in esophageal adenocarcinoma under 200x microscopic magnification (stained cells are marked with an arrow).
Mentions: The average overall Ki-67 index was 23.62 ± 17.6%. The average Ki-67 was 10.29 ± 4.6% in the controls, 21.26 ± 15.1% in the BE patients, and 38 ± 16% in the EAC patients (Figures 3 and 4). Ki-67 increased through groups 1 to 3, and there was a significant difference in the Ki-67 index among all three groups (Figure 5). There was a strong linear correlation (r = 0.6) between Ki-67 and the progression from control to metaplasia to adenocarcinoma (Figure 6) (P < 0.01). No significant interobserver variability was found.

Bottom Line: Ki-67 expression was significantly different between all groups (P < 0.05).In patients with cancer, Ki-67 was not associated with clinical or surgical staging.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Hospital de Clínicas de Porto Alegre, School of Medicine, Federal University of Rio Grande do Sul, 90035-903 Porto Alegre, RS, Brazil.

ABSTRACT
Introduction. The objective of this study was to evaluate Ki-67 antigen expression in patients with Barrett's esophagus and esophageal adenocarcinoma and to assess its correlation with the metaplasia-esophageal adenocarcinoma progression. Methods. Using immunohistochemistry we evaluated the Ki-67 index in patients with Barrett's esophagus, esophageal adenocarcinoma, and controls. We included patients with endoscopically visible columnar mucosa of the distal esophagus (whose biopsies revealed specialized intestinal-type metaplasia), patients with esophageal and esophagogastric tumors types I and II, and patients with histologically normal gastric mucosa (control). Results. In the 57 patients studied there were no statistically significant differences between the groups with respect to age or race. Patients with cancer were predominantly men. The Ki-67 index averaged 10 ± 4 % in patients with normal gastric mucosa (n = 17), 21 ± 15 % in patients with Barrett's esophagus (n = 21), and 38 ± 16 % in patients with cancer (n = 19). Ki-67 expression was significantly different between all groups (P < 0.05). There was a strong linear correlation between Ki-67 expression and the metaplasia-adenocarcinoma sequence (P < 0.01). In patients with cancer, Ki-67 was not associated with clinical or surgical staging. Conclusions. Ki-67 antigen has increased expression along the metaplasia-adenocarcinoma sequence. There is a strong linear correlation between Ki-67 proliferative activity and Barrett's carcinogenesis.

No MeSH data available.


Related in: MedlinePlus